Alpha Tau Medical (DRTS) Investor presentation summary

Technology and therapeutic approach

• Alpha DaRT uses localized alpha particle radiotherapy to precisely destroy solid tumors while sparing healthy tissue, leveraging the decay chain of Radium-224 for targeted cytotoxicity.

• The technology is designed to overcome the short-range limitation of alpha radiation by releasing alpha emitters deeper into tumors, generating a potent and focused radiation distribution.

• Demonstrates broad potential applicability for local tumor control and can be used alone or synergistically with other cancer treatments.

• Over 150 patents issued and more than 200 applications pending, supporting a robust intellectual property position.

Clinical development and milestones

• Multiple upcoming milestones in the next 6–12 months, including pivotal trial recruitment completion and data readouts for cutaneous SCC, pancreatic cancer, and GBM.

• Supportive regulatory dialogue with the FDA and other agencies, with pilot and pivotal studies underway in the US and Japan.

• IDE approval received for pilot studies in GBM and pancreatic cancer in the US.

• Pivotal trial (ReSTART) for recurrent cutaneous SCC ongoing in the US, with marketing authorization already obtained in Israel.

Clinical results and patient outcomes

• In a US pilot study for skin cancer, a 100% complete response rate was observed with no treatment-related serious adverse events.

• Early interim data in head and neck cancer show a 75% systemic objective response rate and 37.5% complete response rate when Alpha DaRT is combined with pembrolizumab.

• Pancreatic cancer trials report a 19% objective response rate and a 97% disease control rate (excluding feasibility patients), with median overall survival since Alpha DaRT of 9.0 months in patients progressed after second-line therapy.

• Preclinical studies in swine brains demonstrated safe and efficient delivery of Alpha DaRT sources with no major complications.